Stock ALK B ALK-ABELLÓ A/S
Add to a list

Company ALK-Abelló A/S

Stocks

ALK B

DK0061802139

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 12:11:10 21/07/2026 BST 		5-day change 1st Jan Change
236.90 DKK -0.29% Intraday chart for ALK-Abelló A/S -1.50% +3.59%
06-15 ALK Receives UK Approval For EURneffy 1 Mg As The First And Only Needle-Free Adrenaline Treatment For Young Children At Risk Of Anaphylaxis CI
06-15 UK Regulator OKs Lower Dose of ALK-Abelló's Severe Allergic Reaction Treatment MT

Business description: ALK-Abelló A/S

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.

Number of employees: 2,759

Sales by Activity: ALK-Abelló A/S

Fiscal Period: December 2021 (DKK) 2022 (DKK) 2023 (DKK) 2024 (DKK) 2025 (DKK)

Allergy Treatment

3.92B 4.51B 4.82B 5.54B 6.31B
See all business segments

Geographical breakdown of sales: ALK-Abelló A/S

Fiscal Period: December 2021 (DKK) 2022 (DKK) 2023 (DKK) 2024 (DKK) 2025 (DKK)

Other Europe

- - 1.23B 1.45B 1.74B

Germany

- - 1.06B 1.38B 1.58B

France

- - 820M 941M 1.01B

USA

- - 772M 775M 884M

International Markets

424M 596M 218M 717M 816M

North America Excl. USA

- - 136M 131M 153M

Denmark

101M 119M 104M 141M 136M

Japan

- - 482M - -

Europe Excl. Denmark

2.71B 2.94B - - -

North America

683M 857M - - -
See all geographic segments

Executive Committee: ALK-Abelló A/S

Manager TitleAgeSince
Peter Halling CEO
 Chief Executive Officer 49 31/12/2023
Claus Steensen Sølje DFI
 Director of Finance/CFO 54 31/05/2023
Per Plotnikof IRC
 Investor Relations Contact - 31/01/2015
Flora Beiche-Scholz PRN
 Corporate Officer/Principal 56 31/12/2024
Lika Thiesen HRO
 Human Resources Officer 51 29/02/2024
See ALK-ABELLÓ A/S governance

Composition of the Board of Directors: ALK-Abelló A/S

Director TitleAgeSince
Katja Barnkob Thalund BRD
 Director/Board Member 57 31/12/2010
Lene Skole-Sørensen BRD
 Director/Board Member 67 31/12/2013
Lars Erik Holmqvist BRD
 Director/Board Member 66 11/03/2015
Nanna Rassov Carlson BRD
 Director/Board Member 50 31/12/2018
Johan Smedsrud BRD
 Director/Board Member 54 31/12/2018
Anders Hedegaard CHM
 Chairman 65 10/03/2020
Gitte Pugholm Aabo BRD
 Director/Board Member 59 17/03/2021
Bertil Lindmark BRD
 Director/Board Member 71 17/03/2021
Alan Main BRD
 Director/Board Member 63 15/03/2022
Lise Lund Mærkedahl BRD
 Director/Board Member 59 31/12/2022
Composition of the Board of Directors

Shareholders: ALK-Abelló A/S

NameStocks%Valuation
Lundbeckfonden
34.31 %
69,496,540 34.31 % 2 596 M kr
Arbejdsmarkedets Tillægspension
4.99 %
10,108,103 4.99 % 378 M kr
ALK-ABELLÓ A/S
0.6226 %
1,261,283 0.6226 % 47 M kr
ÖKOWORLD LUX SA
0.5657 %
1,146,000 0.5657 % 43 M kr
Financière de l'Échiquier SA
0.5255 %
1,064,524 0.5255 % 40 M kr
NameStocks%Valuation
Lundbeckfonden
100 %
18,414,400 100 % 688 M kr
NameStocks%Valuation
Lundbeckfonden
100 %
1,841,440 100 % 69 M kr
List of ALK-ABELLÓ A/S shareholders

Holdings: ALK-Abelló A/S

NameStocks%Valuation
ALK-ABELLÓ A/S
0.62%
1,261,2830.62% 47 M $

Company details: ALK-Abelló A/S

ALK-Abello A/S

Bøge Allé 6-8

2970, Hørsholm

+45 45 74 75 76

http://www.alk.net
address ALK-Abelló A/S(ALK B)

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
ALK-ABELLÓ A/S Stock ALK-Abelló A/S
-0.29%-1.50%+22.82%+222.18% 8.03B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-2.73%-2.96%+48.62%+147.27% 1,023B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.67%-3.47%+52.00%+47.77% 599B
ABBVIE INC. Stock AbbVie Inc.
-0.44%+2.17%+33.88%+78.20% 448B
ROCHE HOLDING AG Stock Roche Holding AG
-0.57%+1.07%+29.30%+20.36% 326B
NOVARTIS AG Stock Novartis AG
+2.66%+3.46%+38.35%+38.78% 278B
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.22%+0.60%+21.56%+15.49% 258B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-1.11%+1.53%-21.00%-41.47% 222B
AMGEN INC. Stock Amgen Inc.
-0.58%+1.03%+23.55%+56.14% 197B
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-0.80%+1.38%+23.09%+66.64% 165B
Average +0.20%-0.46%+27.22%+65.13% 352.31B
Weighted average by Cap. +0.22%-1.18%+35.71%+71.05%
See all sector performances

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

BBB
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
237.60DKK
Average target price
298.75DKK
Spread / Average Target
+25.74%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. ALK B Stock
  4. Company ALK-Abelló A/S

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition